Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Nanoform","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoform Initiates GMP Campaign for First-in-Human Trial of Nanoformed Drug by year End","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"FINLAND","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"Nanoform","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoform Finland Reports First Dosing of Nanoformed Drug Successfully Accomplished","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"FINLAND","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Nanoform","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoform's Clinical Study Indicates Positive Interim Results","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"FINLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Nanoform","sponsor":"Herantis Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nanoform and Herantis sign Biologics Proof of Concept Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Nanoform","sponsor":"Nacuity Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept (\"PoC\") Agreement for Two Ophthalmic Drug Candidates","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"FINLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I"},{"orgOrder":0,"company":"Nanoform","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nanoform's Final Clinical Results Confirm Value Proposition to the Pharma Industry","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"FINLAND","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Nanoform","sponsor":"ONConcept\u00ae Consortium","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FINLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Nanoform","sponsor":"PlusVitech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nanoform and PlusVitech Partner to Repurpose Aprepitant as a Treatment for Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"FINLAND","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Nanoform

    Menu

    Nanoform

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Nanoform

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Finland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nanoform and PlusVitech Partner to Repurpose Aprepitant as a Treatment for Lung Cancer

              Details:

              Under the collaboration, PlusVitech will use Nanoform's state-of-the-art nanomedicine technology to repurpose the anti-nausea medicine aprepitant as a treatment for non-small cell lung cancer.

              Lead Product(s): Aprepitant

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: PlusVitech

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 09, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nanoform

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Finland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide

              Details:

              Enzalutamide is an androgen receptor inhibitor, which is being evaluated in phase 1 clinical trials for the treatment of metastatic castration-resistant prostate cancer.

              Lead Product(s): Enzalutamide

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: ONConcept® Consortium

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 26, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nanoform

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Finland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nanoform's Final Clinical Results Confirm Value Proposition to the Pharma Industry

              Details:

              The primary objective of the study was to determine the PK and relative bioavailability of piroxicam following oral administration of single 20 mg nanoformed piroxicam IR tablets and reference product Felden 20mg tablets (Pfizer) in healthy subjects in the fasted state.

              Lead Product(s): Piroxicam

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nanoform

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Finland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept ("PoC") Agreement for Two Ophthalmic Drug Candidates

              Details:

              Nanoform and Nacuity have signed a Technology Proof of Concept Agreement. This will apply Nanoform’s award-winning nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity’s NPI-001 and NPI-002 drug candidates.

              Lead Product(s): NPI-001

              Therapeutic Area: Ophthalmology Product Name: NPI-001

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Nacuity Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 31, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nanoform

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Finland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nanoform's Clinical Study Indicates Positive Interim Results

              Details:

              Nanoform has received interim study results related to its Phase 1, Study designed to evaluate the pharmacokinetic profile of Piroxicam following administration of Nanoformed oral immediate release Piroxicam tablet and an IR reference product in healthy subjects.

              Lead Product(s): Piroxicam

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nanoform

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Finland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nanoform Finland Reports First Dosing of Nanoformed Drug Successfully Accomplished

              Details:

              First full cohort of twelve healthy volunteers has during the weekend at Quotient Sciences’ facilities in Nottingham, UK, been successfully dosed in the first ever phase 1 human trial of a nanoformed drug candidate using Nanoform’s proprietary CESS® technology.

              Lead Product(s): Piroxicam

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nanoform

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Finland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nanoform and Herantis sign Biologics Proof of Concept Agreement

              Details:

              Nanoform and Herantis have signed a letter of intent to collaborate to seek to enhance nasal drug delivery to the brain of Herantis’ CDNF and xCDNF therapies (Parkinson’s disease) using Nanoform’s proprietary biological nanoparticle technology.

              Lead Product(s): Cerebral Dopamine Neurotrophic Factor

              Therapeutic Area: Neurology Product Name: CDNF

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Recipient: Herantis Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement December 17, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nanoform

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Finland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nanoform Initiates GMP Campaign for First-in-Human Trial of Nanoformed Drug by year End

              Details:

              In the clinical trial, Nanoform will investigate the behavior of an oral immediate release (IR) nanoformed formulation of piroxicam, an anti-inflammatory drug.

              Lead Product(s): Piroxicam

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Quotient Sciences

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 20, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY